6298-46-0

Basic information

• Product Name: N-[2-(3,4-diethoxyphenyl)ethyl]-2-(3,4-diethoxyphenyl)acetamide
• Synonyms: N-[2-(3,4-diethoxyphenyl)ethyl]-2-(3,4-diethoxyphenyl)acetamide;N-[2-(3,4-Diethoxyphenyl)ethyl]-3,4-diethoxybenzeneacetamide;Einecs 228-573-4
• CAS NO: 6298-46-0
• Molecular Formula: C₂₄H₃₃NO₅
• Molecular Weight: 415.52252
• EINECS: 228-573-4
• Mol File: 6298-46-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 595°C at 760 mmHg
• Flash Point: 313.6°C
• Appearance: /
• Density: 1.082g/cm³
• Vapor Pressure: 4.01E-14mmHg at 25°C
• Refractive Index: 1.529
• CAS DataBase Reference: N-[2-(3,4-diethoxyphenyl)ethyl]-2-(3,4-diethoxyphenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2-(3,4-diethoxyphenyl)ethyl]-2-(3,4-diethoxyphenyl)acetamide(6298-46-0)
• EPA Substance Registry System: N-[2-(3,4-diethoxyphenyl)ethyl]-2-(3,4-diethoxyphenyl)acetamide(6298-46-0)

Safety Data

• Hazardous Substances Data: 6298-46-0(Hazardous Substances Data)

Usage

Description

N-[2-(3,4-diethoxyphenyl)ethyl]-2-(3,4-diethoxyphenyl)acetamide is a chemical compound that is identified as an impurity or degradation product of drotaverine (D689700), which is an antispasmodic medication. N-[2-(3,4-diethoxyphenyl)ethyl]-2-(3,4-diethoxyphenyl)acetamide is characterized by its molecular structure that includes diethoxyphenyl groups attached to an amide and acetamide functional groups.

Uses

Used in Pharmaceutical Industry:
N-[2-(3,4-diethoxyphenyl)ethyl]-2-(3,4-diethoxyphenyl)acetamide is used as an impurity/degradation product for [application type] in the pharmaceutical industry. Its presence is significant for [application reason] ensuring the quality, safety, and efficacy of drotaverine, an antispasmodic medication. Monitoring and controlling the levels of this compound in the manufacturing process can help maintain the desired therapeutic effects and minimize potential side effects associated with drotaverine use.

InChI:InChI=1/C24H33NO5/c1-5-27-20-11-9-18(15-22(20)29-7-3)13-14-25-24(26)17-19-10-12-21(28-6-2)23(16-19)30-8-4/h9-12,15-16H,5-8,13-14,17H2,1-4H3,(H,25,26)

Upstream product

• 17345-77-6 1-bromo-3,4-dihydroxybenzene 
• 53207-08-2 4-bromo-1,2-diethoxybenzene 
• 279262-08-7 3,4-diethoxyphenylboronic acid 
• 1005009-95-9 2-(3,4-diethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 69373-87-1 ethyl 2-(3,4-diethoxyphenyl)acetate 
• 92157-09-0 methyl 2-(3,4-diethoxyphenyl)acetate 
• 526190-09-0 2-(3,4-diethoxyphenyl)acetamide 
• 38464-04-9 3,4-diethoxy-phenyl-acetic acid 
• 53017-34-8 ethyl 2-(3,4-diethoxyphenyl)-2-oxoacetate 
• 2050-46-6 1,2-diethoxybenzene 
• 1137-71-9 1-(3,4-diethoxyphenyl)ethanone 
• 61381-04-2 2-(3,4-diethoxyphenyl)ethylamine 

Downstream Products

• 985-12-6 1-(3,4-diethoxybenzylidene)-6,7-diethoxy-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 486-47-5 ethaverine 
• 861-27-8 1-(3',4'-diethoxy-benzyl)-6,7-diethoxy-3,4-dihydro-isoquinoline 

Relevant articles and documents

Novel method for preparing drotaverine hydrochloride intermediate

The invention discloses a novel method for preparing a drotaverine hydrochloride intermediate, belonging to the technical field of medicine synthesis. The preparation method comprises the following steps: preparing an intermediate 3,4-diethoxyphenylacetic acid with 1,2-diethoxybenzene as a raw material, and preparing the intermediate 3,4-diethoxyphenylacetamide with 3,4-diethoxyphenylacetic acid as a raw material. According to the novel process for preparing the drotaverine hydrochloride intermediate, a method for directly preparing 3,4-diethoxyphenylacetic acid and 3,4-diethoxyphenylethylamine is adopted, and a process for preparing 3,4-diethoxyphenylacetonitrile is avoided, so a reaction step of using sodium cyanide is avoided.